Invokana (or Invokamet or Invokamet XR), is associated with an elevated risk of amputation of the leg, foot and toes. In fact, the FDA has updated the warnings on these medications to reflect the risk. These medications are sodium-glucose cotransporter 2 (SGLT2) inhibitors, drugs used to treat Type II diabetes.
Accepting Clients Throughout New Jersey Including Hackensack, Bergen County, Newark & Essex County
A cancer diagnosis brings fear and uncertainty; the hair loss that has come to be recognized as a symbol of chemotherapy often amplifies the sense of loss of personal control that cancer brings.
In conjunction with a healthy diet and exercise, diabetes treatments like Invokana have been shown to help lower blood sugar levels in patients with type 2 diabetes. This new class of diabetes drugs, known as SGLT2 inhibitors, is not without risks, cautions the FDA, which has received adverse event reports detailing high blood acid levels requiring patient hospitalization.
Attorneys at Eisbrouch Marsh have been concerned for some time about the serious side effects, mostly heart attacks and strokes, suffered by some men who have received testosterone therapy.
Takeda Pharmaceuticals has offered a $2.2 billion Actos settlement to resolve current claims that the diabetes medicine causes bladder cancer, sources say. The offer was disclosed to Bloomberg News by three sources close to the company who wish to remain anonymous because they do not have authorization to speak on the matter.